Neurocrine Biosciences, Inc. $NBIX Shares Sold by Atle Fund Management AB

Atle Fund Management AB cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,796 shares of the company’s stock after selling 7,829 shares during the period. Neurocrine Biosciences accounts for approximately 4.3% of Atle Fund Management AB’s investment portfolio, making the stock its 5th biggest holding. Atle Fund Management AB’s holdings in Neurocrine Biosciences were worth $13,445,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. USA Financial Formulas acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at about $25,000. Geneos Wealth Management Inc. boosted its stake in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after purchasing an additional 100 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Neurocrine Biosciences during the 3rd quarter valued at about $49,000. Finally, Smartleaf Asset Management LLC boosted its stake in Neurocrine Biosciences by 112.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 424 shares of the company’s stock valued at $59,000 after purchasing an additional 224 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 1.8%

NASDAQ:NBIX opened at $154.36 on Wednesday. The stock has a market capitalization of $15.52 billion, a PE ratio of 23.78, a price-to-earnings-growth ratio of 1.18 and a beta of 0.34. The firm’s 50 day moving average is $135.12 and its 200 day moving average is $138.57. Neurocrine Biosciences, Inc. has a 12 month low of $117.59 and a 12 month high of $162.39.

Insider Buying and Selling

In related news, Director Leslie V. Norwalk sold 3,810 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $155.01, for a total value of $590,588.10. Following the sale, the director owned 2,429 shares of the company’s stock, valued at approximately $376,519.29. The trade was a 61.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the sale, the director directly owned 34,480 shares in the company, valued at $5,435,772. This trade represents a 30.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NBIX. UBS Group cut their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Guggenheim reiterated a “buy” rating and set a $175.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 6th. BMO Capital Markets cut their price target on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a research note on Thursday, February 12th. HC Wainwright boosted their target price on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Finally, Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $184.15.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.